Barua Souptik, Sabharwal Ashutosh, Glantz Namino, Conneely Casey, Larez Arianna, Bevier Wendy, Kerr David
Electrical and Computer Engineering, Rice University, Houston, TX, USA.
Sansum Diabetes Research Institute, Santa Barbara, CA, USA.
EClinicalMedicine. 2021 Apr 25;35:100853. doi: 10.1016/j.eclinm.2021.100853. eCollection 2021 May.
Continuous glucose monitoring (CGM) has demonstrable benefits for people living with diabetes, but the supporting evidence is almost exclusively from White individuals with type 1 diabetes. Here, we have quantified CGM profiles in Hispanic/Latino adults with or at-risk of non-insulin treated type 2 diabetes (T2D).
100 participants (79 female, 86% Hispanic/Latino [predominantly Mexican], age 54·6 [±12·0] years) stratified into (i) at risk of T2D, (ii) with pre-diabetes (pre-T2D), and (iii) with non-insulin treated T2D, wore blinded CGMs for 2 weeks. Beyond standardized CGM measures (average glucose, glucose variability, time in 70-140 mg/dL and 70-180 mg/dL ranges), we also examined additional CGM measures based on the time of day.
Standardized CGM measures were significantly different for participants with T2D compared to at-risk and pre-T2D participants (<0·0001). In addition, pre-T2D participants spent more time between 140 and 180 mg/dL during the day than at-risk participants (<0·01). T2D participants spent more time between 140 and 180 mg/dL both during the day and overnight compared to at-risk and pre-T2D participants (both <0·0001). Time in 70-140 mg/dL range during the day was significantly correlated with HbA (=-0·72, <0·0001), after adjusting for age, sex, BMI, and waist circumference (<0·0001).
Standardized CGM measures show a progression of dysglycemia from at-risk of T2D, to pre-T2D, and to T2D. Stratifying CGM readings by time of day and the range 140-180 mg/dL provides additional metrics to differentiate between the groups.
US Department of Agriculture (Grant #2018-33800-28404) and NSF PATHS-UP ERC (Award #1648451).
连续血糖监测（CGM）对糖尿病患者有显著益处，但支持证据几乎完全来自患有1型糖尿病的白人个体。在此，我们对患有非胰岛素治疗的2型糖尿病（T2D）或有患T2D风险的西班牙裔/拉丁裔成年人的CGM情况进行了量化。
100名参与者（79名女性，86%为西班牙裔/拉丁裔[主要是墨西哥人]，年龄54.6[±12.0]岁）被分为三组：（i）有患T2D风险的，（ii）患有糖尿病前期（糖尿病前期）的，以及（iii）患有非胰岛素治疗的T2D的，佩戴盲法CGM两周。除了标准化的CGM测量指标（平均血糖、血糖变异性、血糖在70 - 140mg/dL和70 - 180mg/dL范围内的时间）外，我们还根据一天中的时间检查了其他CGM测量指标。
与有患T2D风险和糖尿病前期的参与者相比，患有T2D的参与者的标准化CGM测量指标有显著差异（<0.0001）。此外，糖尿病前期参与者白天血糖在140至180mg/dL之间的时间比有患T2D风险的参与者更长（<0.01）。与有患T2D风险和糖尿病前期的参与者相比，患有T2D的参与者白天和夜间血糖在140至180mg/dL之间的时间都更长（均<0.0001）。在调整年龄、性别、体重指数和腰围后，白天血糖在70 - 140mg/dL范围内的时间与糖化血红蛋白显著相关（=-0.72，<0.0001）（<0.0001）。
标准化的CGM测量指标显示了血糖异常从有患T2D风险到糖尿病前期再到T2D的进展过程。按一天中的时间以及140 - 180mg/dL范围对CGM读数进行分层，提供了区分不同组别的额外指标。
美国农业部（资助编号#2018 - 33800 - 28404）和美国国家科学基金会PATHS - UP工程研究中心（奖项编号#1648451）。
